International Workshop on CAR-T (iwCAR-T) 2021

21 – 23 April 2021

VJHemOnc is proud to be an official media partner for iwCAR-T 2021, a high-level discussion forum for research leaders in the field of CAR-T. Some of the world’s leading clinical researchers in the field will share their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care. The overriding objectives of the iwCAR-T are to facilitate global scientific interaction and exchange focusing on top-tier research endeavors.

The iwCAR-T 2021 meeting Scientific Committee has targeted areas for discussion where new evidence, insights, therapies and approaches, have important clinical implications, including:

  • The use of CAR-T in hematological malignancies
  • Evolution of cellular therapies
  • Current progress in CAR-T for solid tumors

This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.

Agenda (all times EST)

Wednesday 21st April 2021

10.00:10:05 EST Introduction & Meeting Objectives: John Gribben & David Maloney

10.05-11.00 Session 1: CAR-T in AML | Chairs: Saar Gill & John DiPersio

  • Clinical update on CAR T-cell therapy for AML: Saar Gill
  • Role of CAR T-cells in the treatment of pediatric AML: Richard Aplenc
  • CAR-T or BiTE in AML?: Marion Subklewe
  • NK cells and CAR NK cells for AML: Rizwan Romee

Panel discussion

11:00-12:20 Session 2: CAR-T in ALL | Chairs: Noelle Frey & Bijal Shah

CAR-T in ALL:

  • Allogeneic CAR-Ts for ALL: Reuben Benjamin
  • Factors associated with durable remissions after CAR-T: Cameron Turtle
  • Adult ALL and CART19: Claire Roddie
  • Approaches to Dual Targeting with CARTs: Nirali Shah
  • Updates on Neurotoxicity: Bianca Santomasso
  • Bridging therapy and role of HSCT after CART: Jae Park

Panel Discussion

12.20-13:20 Session 3: CAR-T in CLL  | Chairs: John Gribben & David Porter

  • Combining ibrutinib with CD19 CAR T-cells for CLL: Jordan Gauthier
  • Transcend/JCAR – liso-cel: Tanya Siddiqi
  • CAR NK treatments in CLL: Loretta Nastoupil
  • CAR T-cells for CLL: When can we use the word ‘cure’?: David Porter

Panel Discussion

Day 1, Conclusions & Wrap up

Thursday 22nd April 2021

10.00am EST Introduction/Welcome

10.00-11:20 Session 4: CAR-T in Myeloma  | Chairs: Yi Lin & Noopur Raje

  • BCMA CAR-Ts – Ide-cel/bb2121: Nina Shah
  • Ciltacabtagene Autoleucel (Cilta-cel) – CARTITUDE; Saad Usmani
  • Allo-CAR-T: Sham Mailankody
  • TCE – BCMA and non-BCMA targets: Adam Cohen
  • CAR-T in myeloma in China: Wang Jianxiang
  • BiTEs vs CARs: Maria-Victoria Mateos

Panel Discussion

11.20-12:45 Session 5: Evolution of cellular therapies  | Chairs: David Maloney & Yi Lin

  • Epigenetics of CAR T-cells: Michel Sadelain
  • Synthetic CARs: Wendell Lim
  • Logic-gated cell therapy: William Go
  • Using CRISPR to enhance Immune cellular function: Eric Shifrut
  • Innovative CAR designs: Renier Bretjens

Panel Discussion

Day 2, Conclusions & Wrap up

Friday 23rd April 2021

10.00am EST Welcome/Introduction

10.00-11:45 Session 6: Where are we with emerging cell therapies in solid tumors? | Chairs: Stanley Riddell & Jennifer Specht

  • alloSHRINK – non-gene edited allogeneic CAR-T in mCRC: Sebastien Anguille
  • CAR T-cells in mCRPC: Vivek Narayan
  • ROR-1 in breast and lung cancer: Jennifer Specht
  • CAR T-cell Therapy in Glioblastoma: Christine Brown

Panel Discussion

  • Signaling in solid tumors: Stanley Riddell
  • Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4: David Hong
  • Auto TILs Lifileucel (LN-144) for metastatic melanoma: Amod Sarnaik
  • Cell therapy trial updates in lung cancer and mesothelioma: Melissa Johnson

Panel Discussion

11.45-13:00 Session 7: Lymphoma | Chair: Frederick Locke & Caron Jacobson

  • Axi-cel in DLBCL and FL: Caron Jacobson
  • Tisagenlecleucel in DLBCL/FL: Stephen Schuster
  • Liso-cel in DLBCL: Jeremy Abramson
  • Updates in MCL: Frederick Locke

Panel Discussion

  • Dual CAR: David Miklos
  • Third generation CD20 targeted CAR T-cell therapy: Mayzar Shadman
  • A new era of targeted therapy: Sonali Smith

Panel Discussion

Day 3, Conclusions & Wrap up

END

This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter